PolyTherics Raises £3 million to Commercialise PEGylationTechnologies
PolyTherics Limited announced the completion of an investment round of £3.0 million in the company. The investment round was led by Imperial Innovations Group plc, the technology investment and commercialisation company, and included Longbow Capital and The Capital Fund. This investment follows on from a £2.3 million financing backed by the same syndicate in June 2007.
Since commencement of operations in 2002, PolyTherics has developed a suite of technologies to improve the properties of biologics for therapeutic use. Having successfully out-licensed its targeted PEGylation technology TheraPEG™ to several commercial partners, the Company intends to use these new funds to exemplify its PEGylation platforms, HiPEG™ and CyPEG in the context of novel peptides and proteins as potential ‘biobetter’ products. PolyTherics intends to continue to out-license its PEGylation technologies while seeking external grants to support its research.
Robert Bahns of Imperial Innovations joins the Board of PolyTherics at this investment round, while Till Medinger and Stephane Mery resign from their non-executive director positions.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.